Treating Multiline Treatment Failure in Advanced Colon Cancer Based on Evolutionary Theory: A Case Report
Xinyu Wu1, Qingying Xian1, Rui Ling1
1Department of Oncology, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, People's Republic of China.
Purpose:
Currently, there is no standard regimen for third-line therapy in advanced colon cancer. Intratumoral heterogeneity and tumor evolution have been substantiated in multiple cancer types, paving the way for exploratory research into new treatment strategies for pulmonary metastases from colorectal cancer.
Patients And Methods:
In this report, we present a case of advanced colon cancer with lung metastasis. After multiple lines of therapy (including FOLFOX, FOLFIRI combined with targeted therapy) failed, the patient received a lung cancer-derived regimen to colorectal pulmonary metastases through an evolutionary perspective.
Results:
After two cycles, the patient achieved partial response (PR), and after eight cycles, the disease was stable (SD), with a good quality of life.
Conclusion:
The application of a lung cancer-derived regimen to colorectal pulmonary metastases through an evolutionary perspective may offer a new therapeutic direction for patients who have exhausted standard options.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...